Cogent Biosciences' NDA for Bezuclastinib Accepted by FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy COGT?
Source: Newsfilter
- FDA NDA Acceptance: Cogent Biosciences' New Drug Application for bezuclastinib targeting Non-Advanced Systemic Mastocytosis has been accepted by the FDA, with a PDUFA target action date set for December 30, 2026, indicating significant progress in the precision therapy sector.
- Significant Clinical Results: Data from the SUMMIT trial demonstrated that bezuclastinib achieved clinically meaningful improvements across primary and key secondary endpoints in Non-AdvSM patients, supporting its potential for sustained clinical benefits with longer therapy duration.
- Favorable Safety Profile: The SUMMIT trial results indicated that bezuclastinib has a favorable safety and tolerability profile, suggesting its potential for chronic use in Non-AdvSM patients, which could enhance patient quality of life.
- Future Submission Plans: The company is on track to complete its NDA submission for bezuclastinib in patients with Gastrointestinal Stromal Tumors by April 2026 and expects to submit for Advanced Systemic Mastocytosis in the first half of 2026, further expanding its product pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COGT
Wall Street analysts forecast COGT stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 36.100
Low
34.00
Averages
50.36
High
67.00
Current: 36.100
Low
34.00
Averages
50.36
High
67.00
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RTW Investments Increases Stake in Cogent Biosciences Significantly
- Stake Increase: RTW Investments disclosed a significant purchase of 4,124,755 shares in Cogent Biosciences in its SEC filing dated February 17, 2026, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future.
- Market Value Growth: Following this purchase, Cogent's quarter-end position value rose to $219.88 million, reflecting optimistic market expectations regarding its potential in the precision medicine sector, particularly for genetically defined diseases.
- Portfolio Dynamics: RTW's stake in Cogent now represents 2.7% of its 13F reportable AUM, while its top holdings like MDGL and INSM also show robust market performance, highlighting the diversity of its investment strategy.
- Clinical Success Outlook: Cogent Biosciences' stock price surged 360% over the past year, and with its lead candidate's FDA application accepted, a crucial decision is expected by late 2026, which could further propel the stock's upward trajectory.
See More
RTW Investments Increases Stake in Cogent Biosciences
- Share Increase Details: RTW Investments added 4,124,755 shares of Cogent Biosciences in Q4 2026, with an estimated trade value of $115.95 million, indicating strong confidence in the company's future prospects.
- Holding Value Growth: By quarter-end, RTW's total holdings reached 7,592,241 shares valued at $269.68 million, reflecting a $219.88 million increase, which underscores market recognition and appreciation of Cogent's stock.
- Company Financial Health: Cogent Biosciences ended the year with approximately $900 million on its balance sheet, providing sufficient runway into 2028 while advancing multiple regulatory filings related to its lead drug, showcasing its robust R&D capabilities.
- Market Outlook Analysis: Despite a 360% surge in Cogent's stock price, its competitive edge in precision medicine and upcoming FDA decisions could yield substantial returns for investors, indicating significant future growth potential.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48.38 Million
- Share Reduction Details: Kynam Capital disclosed in a February 17, 2026 SEC filing that it sold 1,720,949 shares of Cogent Biosciences, translating to an estimated $48.38 million trade, indicating a disciplined approach to risk management while maintaining a significant position.
- Asset Management Proportion: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, remaining the fund's largest single position, which reflects ongoing confidence in the company's growth potential despite the reduction.
- Market Performance: As of last Friday, shares of Cogent Biosciences were priced at $33.38, having surged 360% over the past year, significantly outperforming the S&P 500's 15% gain, highlighting its strong market presence and investor interest in the biotech sector.
- Financial Status and Outlook: Cogent ended 2022 with $900.8 million in cash and equivalents, sufficient to fund operations into 2028, while its product bezuclastinib received FDA acceptance, with a target action date of December 30, further bolstering market confidence in its future prospects.
See More
Kynam Capital Reduces Stake in Cogent Biosciences
- Share Reduction Details: Kynam Capital sold 1,720,949 shares of Cogent Biosciences in Q4 2026, with an estimated transaction value of $48.38 million, demonstrating the fund's agility in response to market fluctuations.
- Value Change Post-Sale: After the sale, the fund retained 6,165,223 shares valued at approximately $218.99 million, maintaining its position as the largest single holding in its portfolio, indicating sustained confidence in Cogent's long-term prospects.
- Market Reaction and Strategy: The quarter-end valuation of Cogent changed by $105.74 million due to trading and stock price movements, reflecting strong market interest in its biotechnology innovations, especially following the FDA's acceptance of its new drug application.
- Future Outlook: Cogent ended 2026 with $900.8 million in cash and cash equivalents, sufficient to fund operations into 2028, showcasing its financial stability and potential for continued growth.
See More
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
- Stake Reduction: Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, with an estimated transaction value of $81.11 million, indicating a cautious outlook on the company's future performance.
- Holding Proportion Change: Following this transaction, Kynam's stake in Viridian decreased to 2.92%, reflecting a reassessment of asset allocation in its 13F report, which may impact investor confidence in the company.
- Market Performance: Viridian's stock price has surged 76% over the past year, currently priced at $26.98, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market demand for its biotech products.
- R&D Expenditure: Despite facing nearly $339 million in R&D costs and an annual net loss of about $343 million, Viridian's cash reserves of approximately $875 million at year-end provide a financial cushion for future clinical trials and product launches.
See More
RTW Investments Increases Stake in Cogent Biosciences Significantly
- Stake Increase: RTW Investments disclosed a significant purchase of 4,124,755 shares in Cogent Biosciences in its SEC filing dated February 17, 2026, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future.
- Market Value Growth: Following this purchase, Cogent's quarter-end position value rose to $219.88 million, reflecting optimistic market expectations regarding its potential in the precision medicine sector, particularly for genetically defined diseases.
- Portfolio Dynamics: RTW's stake in Cogent now represents 2.7% of its 13F reportable AUM, while its top holdings like MDGL and INSM also show robust market performance, highlighting the diversity of its investment strategy.
- Clinical Success Outlook: Cogent Biosciences' stock price surged 360% over the past year, and with its lead candidate's FDA application accepted, a crucial decision is expected by late 2026, which could further propel the stock's upward trajectory.
See More
RTW Investments Increases Stake in Cogent Biosciences
- Share Increase Details: RTW Investments added 4,124,755 shares of Cogent Biosciences in Q4 2026, with an estimated trade value of $115.95 million, indicating strong confidence in the company's future prospects.
- Holding Value Growth: By quarter-end, RTW's total holdings reached 7,592,241 shares valued at $269.68 million, reflecting a $219.88 million increase, which underscores market recognition and appreciation of Cogent's stock.
- Company Financial Health: Cogent Biosciences ended the year with approximately $900 million on its balance sheet, providing sufficient runway into 2028 while advancing multiple regulatory filings related to its lead drug, showcasing its robust R&D capabilities.
- Market Outlook Analysis: Despite a 360% surge in Cogent's stock price, its competitive edge in precision medicine and upcoming FDA decisions could yield substantial returns for investors, indicating significant future growth potential.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48.38 Million
- Share Reduction Details: Kynam Capital disclosed in a February 17, 2026 SEC filing that it sold 1,720,949 shares of Cogent Biosciences, translating to an estimated $48.38 million trade, indicating a disciplined approach to risk management while maintaining a significant position.
- Asset Management Proportion: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, remaining the fund's largest single position, which reflects ongoing confidence in the company's growth potential despite the reduction.
- Market Performance: As of last Friday, shares of Cogent Biosciences were priced at $33.38, having surged 360% over the past year, significantly outperforming the S&P 500's 15% gain, highlighting its strong market presence and investor interest in the biotech sector.
- Financial Status and Outlook: Cogent ended 2022 with $900.8 million in cash and equivalents, sufficient to fund operations into 2028, while its product bezuclastinib received FDA acceptance, with a target action date of December 30, further bolstering market confidence in its future prospects.
See More
Kynam Capital Reduces Stake in Cogent Biosciences
- Share Reduction Details: Kynam Capital sold 1,720,949 shares of Cogent Biosciences in Q4 2026, with an estimated transaction value of $48.38 million, demonstrating the fund's agility in response to market fluctuations.
- Value Change Post-Sale: After the sale, the fund retained 6,165,223 shares valued at approximately $218.99 million, maintaining its position as the largest single holding in its portfolio, indicating sustained confidence in Cogent's long-term prospects.
- Market Reaction and Strategy: The quarter-end valuation of Cogent changed by $105.74 million due to trading and stock price movements, reflecting strong market interest in its biotechnology innovations, especially following the FDA's acceptance of its new drug application.
- Future Outlook: Cogent ended 2026 with $900.8 million in cash and cash equivalents, sufficient to fund operations into 2028, showcasing its financial stability and potential for continued growth.
See More
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
- Stake Reduction: Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, with an estimated transaction value of $81.11 million, indicating a cautious outlook on the company's future performance.
- Holding Proportion Change: Following this transaction, Kynam's stake in Viridian decreased to 2.92%, reflecting a reassessment of asset allocation in its 13F report, which may impact investor confidence in the company.
- Market Performance: Viridian's stock price has surged 76% over the past year, currently priced at $26.98, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market demand for its biotech products.
- R&D Expenditure: Despite facing nearly $339 million in R&D costs and an annual net loss of about $343 million, Viridian's cash reserves of approximately $875 million at year-end provide a financial cushion for future clinical trials and product launches.
See More
